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As the identification of new targets for therapeutic intervention that might attenuate 
cardiovascular complications associated with type 2 diabetes are needed, our lab 
conducted a prior study to address that need. We reported at that time that mice treated 
with a potent and selective small molecule inhibitor (LB1; Lixte Biotechnology Holdings, 
Inc., East Setauket, NY; 1 mg/kg IP; intraperitoneal) of protein phosphatase 2A (PP2A) 
for the last 14 days of an obesogenic diet (12 weeks of fat-feeding) did not display 
vascular PP2A hyperactivation, endothelial dysfunction, or hypertension that otherwise 
developed in fat-fed mice treated with vehicle. We concluded that PP2A hyperactivation 
should be considered further as a therapeutic target for intervention. While our 
investigation was in progress, results from another study indicated that 2 -mg/kg LB1 IP 
(3 hr) evoked hyperglycemia, glucose intolerance, and hepatic glycogen depletion in 
chow-fed and fat-fed (3 days) rats. The authors concluded that targeting PP2A 
hyperactivation should not be considered as a therapeutic intervention. Based on the 
incongruent conclusions from these two studies, we conducted a new research study, 
testing the following hypotheses—that LB1 treatment for 14-days impairs: (i) peripheral 
glucose homeostasis; (ii) hepatic glycogen content; and (iii) insulin-mediated signal 
transduction in the liver. The first two hypotheses were tested using 7-week old male 
C57BL/6J mice who consumed standard (Con) or high fat (HF) chow for 12 weeks. 





days of testing. Glucose and insulin tolerance testing indicated that LB1 treatment does 
not impair peripheral glucose homeostasis in Con mice or HF mice, denying the first 
hypothesis. Regarding second hypothesis, LB1 treatment did not lower hepatic glycogen 
content, p-Akt2S474 / Akt2, p-Gsk3ɑS21 / Gsk3ɑβ, or p-GSS641 / GS, in lean or obese mice 
under basal, random-fed conditions. To test the third hypothesis, age-matched male mice 
that consumed standard chow were treated with LB1 or Veh for 14 days. On day 15, after 
a 6-hr fast, insulin or saline was administered (i.v.; intravenous) to anesthetized mice, and 
segments of liver were collected to assess p-Akt2S474 / Akt2, p-GSK3ɑS21 / GSK3ɑ, and 
p-GSS641 / GS. Insulin-mediated signal transduction in the liver was similar regardless of 
LB1 treatment. We conclude that LB1 treatment in mice for 14-days does not impair: (i) 
peripheral glucose homeostasis; (ii) hepatic glycogen content; or (iii) insulin-mediated 
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Obesity, type 2 diabetes mellitus (T2DM), and insulin resistance are conditions 
associated with an altered endothelial cell (EC) phenotype that is, endothelial dysfunction. 
Eighty percent of patients with these conditions will die from cardiovascular 
complications. The prevalence of diagnosed and undiagnosed cases of T2DM is 
estimated to increase to 33% by 2050 (Boyle, Thompson, Gregg, Barker, & Williamson, 
2010). Individual and societal costs will increase should this concerning projection be 
realized. This underscores the need to elucidate effective therapeutic targets and 
strategies for intervention. 
 
1.1 Literature Review  
1.1.1 Endothelial cell dysfunction 
Endothelial dysfunction can be defined as attenuated arterial vasorelaxation in 
response to pharmacological agonists such as acetylcholine, bradykinin, or adenosine 
triphosphate (ATP), or physical stimuli such as increased intraluminal flow. When 
impaired vasorelaxation to one of these agonists is observed and the integrity of the 
vascular smooth muscle is verified, a strong case can be made that the endothelium is the 





endothelial dysfunction (Triggle & Ding, 2010). A crucial aspect of endothelial 
dysfunction is reduced nitric oxide (NO) bioavailability. NO bioavailability depends on a 
delicate balance between factors responsible for the synthesis and degradation of this 
molecule. In addition to contributing to vasodilation, endothelial cell derived NO has 
anticoagulant, anti-inflammatory, and antiproliferative properties (Alderton, Cooper, & 
Knowles, 2001; Sessa, 2004; Shaul, 2002). Loss of these protective mechanisms 
contributes importantly to the pathophysiology of micro and macrovascular diseases that 
characterizes obesity, T2DM, and insulin resistance (Symons, 2013; Symons & Abel, 
2013; Triggle & Ding, 2010).  
Progress has been made in elucidating general mechanisms that precipitate a 
mismatch between generation and degradation of NO that leads to cardiovascular 
complications such as hypertension and atherosclerosis that are associated with 
endothelial dysfunction. Strong evidence exists that hyperglycemia, oxidative stress, 
activation of the renin angiotensin system, increased proinflammatory cytokines, and 
lipotoxicity contribute independently and synergistically to this process (Bornfeldt & 
Tabas, 2011; Geraldes & King, 2010) (Figure 1). Gaining additional insight into precise 
mechanisms linking each of these pathways to vascular dysfunction is necessary to 
design and implement targeted therapeutic strategies with minimal off-target side effects. 
Our recent focus has concerned the contribution from lipotoxicity in general, and the lipid 
metabolite ceramide in particular, to lowering vascular NO production to an extent that 
precipitates endothelial cell dysfunction (Bharath et al., 2015; Symons et al., 2009; 






1.1.2 Elevated free fatty acids contribute importantly to endothelial  
dysfunction that is observed in obese versus lean mice 
Earlier we reported that a dissociation exists between insulin mediated signal 
transduction in the vasculature, and impaired endothelial nitric oxide synthase (eNOS) 
enzyme function (Symons et al., 2009). In this regard, systemic hypertension, arterial 
dysfunction, and decreased basal and stimulated eNOS phosphorylation in obese mice 
occurred in the absence of evidence for deficient signaling via Protein kinase B (Akt) to 
eNOS in the vasculature (Symons et al., 2009). The apparent dissociation between 
vascular insulin signaling and impaired eNOS enzyme function in the context of obesity 
prompted an exploration into whether a component of the metabolic environment or 
altered signaling via another kinase to eNOS might play a role. Because fasting 
hyperglycemia was mild in fat-fed versus lean mice in that study, and superoxide anion 
(O2•-) production, nicotinamide adenine dinucleotide phosphate (NADPH)-oxidase 
activity, adenosine monophosphate-activated protein kinase (AMPK), and Protein Kinase 
A (PKA) were similar in vessels from both groups, the contribution from the three-fold 
elevation in free fatty acids (FFAs) in obese versus lean mice was explored more 
thoroughly. To do so, bovine aortic endothelial cells (BAECs) were treated with 500 uM 
palmitate, a concentration that lies within the physiological / pathophysiological range 
(Summers, 2010) and does not lead to cell death or apoptosis in response to exposures ˂ 
3 hr (Symons et al., 2009).  Compared to vehicle-treated cells, palmitate impaired basal 
and insulin-stimulated eNOS phosphorylation at serine 1117 (p-eNOSS1177) whereas 
extracellular signal–regulated kinases (ERK) and Akt phosphorylation was intact. 





compromise insulin-mediated NO generation by BAECs (assessed by amperometric 
probes), and attenuate endothelium-dependent vasorelaxation but not vascular smooth 
muscle function of isolated arteries (Symons et al., 2009) (assessed by isometric tension 
techniques). These in vitro results from BAECs and isolated arteries exposed to palmitate 
recapitulated earlier observations from arteries of obese mice in the same study, and 
indicate a significant component of endothelial dysfunction in obese mice is secondary to 
elevated FFAs.   
 
1.1.3 The FFA metabolite ceramide contributes importantly to??????????????  
dysfunction that is observed in obese versus lean mice 
When tissues not suited for lipid storage (e.g., skeletal muscle, liver) are exposed to 
increased circulating levels of FFAs, toxic bioactive lipid metabolites can accumulate and 
that might be associated with impaired metabolic homeostasis and increased 
cardiovascular risk. One such metabolite is the sphingolipid ceramide (Chun et al., 2011; 
Holland & Summers, 2008). Obesity and lipid exposure promote sphingolipid 
accumulation in peripheral tissues of rodents and humans, and ceramide accumulates in 
arteries from rats with uncontrolled type 2 diabetes (Wu, Song, Xu, Zhang, & Zou, 2007). 
Based on these reports, and our earlier findings in BAECs and isolated arteries that 
palmitate decreases p-eNOSS1177, NO production, and endothelial but not vascular 
smooth muscle function (Symons et al., 2009), the specific contribution from the FFA 
metabolite ceramide was investigated (Zhang et al., 2012). In that study, palmitate 
increased de novo ceramide synthesis in BAECs, which reduced insulin and vascular 





monomer formation, eNOS enzyme activity, and NO production (Zhang et al., 2012). 
Importantly, each effect of ceramide was negated when BAECs were incubated with 
palmitate concurrently with myriocin, an inhibitor of the rate limiting enzyme responsible 
for ceramide biosynthesis. In contrast to findings from other cell types (Holland et al., 
2007), palmitate-induced ceramide accumulation in BAECs did not impair upstream 
signaling to eNOS from Akt, AMPK, or ERK 1/2, or increase O2•- -mediated 
peroxynitrite formation to an extent that compromised NO generation. In addition to 
BAECs, palmitate also increased endogenous ceramide biosynthesis in isolated arteries. 
Notably, when palmitate-induced arterial ceramide biosynthesis was prevented using 
pharmacological and genetic approaches, the ability of this FFA to decrease p-eNOSS1177 
and endothelium-dependent vasorelaxation was prevented (Zhang et al., 2012). 
Collectively, these findings from BAECs and isolated arteries indicate that ceramide 
contributes importantly to palmitate-induced reductions in eNOS activation to an extent 
that is functionally relevant. 
Next it was important to determine whether deleterious responses to ceramide 
accumulation observed in BAECs and isolated arteries after relatively short term (i.e., 3 
hr) exposure to palmitate could be observed in a clinically relevant rodent model of 
obesity, T2DM, and insulin resistance (Zhang et al., 2012). As such, pharmacological and 
genetic approaches to limit ceramide biosynthesis in fat-fed mice were implemented to 
determine whether earlier findings from BAECs and isolated arteries could be 
recapitulated in vivo. Inhibition of ceramide synthesis with myriocin, or by heterozygous 
deletion of dihydroceramide desaturase (des1), which catalyzes de novo ceramide 





eNOS phosphorylation in arteries from fat-fed mice (Zhang et al., 2012). Collectively, 
these studies support the hypothesis that arterial ceramide accumulation precipitates 
cellular dysfunction in part by impairing NO bioavailability.  
 
1.1.4 Endothelial dysfunction is caused by palmitate-induced,  
ceramide-mediated, protein phosphatase 2A association 
with eNOS 
After observing that palmitate and fat-feeding impair eNOS phosphorylation, NO 
production, and arterial vasorelaxation in a ceramide-dependent manner, our laboratory 
sought to elucidate the molecular mechanisms that might be responsible. Protein kinases 
and phosphatases respectively add and remove phosphate groups from their target 
proteins (Shi, 2009). Because ceramide did not alter kinase signaling to eNOS or 
exaggerate reactive oxygen species (ROS)-mediated destruction of eNOS (Symons et al., 
2009; Zhang et al., 2012), intracellular phosphatases were examined. Protein 
phosphatases 1 (PP1), 2A (PP2A), and 2B (PP2B) are abundantly expressed in tissues 
from diabetic rats and all have potential to negatively regulate p-eNOSS1177 (Foulkes & 
Jefferson, 1984; Mehra et al., 2014; Smith, Visioli, Frei & Hagen, 2006; Wu, Song, Xu, 
Zhang, & Zou, 2007). While preliminary results from BAECs revealed that neither PP1 
nor PP2B contributed importantly to palmitate-induced reductions in p-eNOSS1177 
(Bharath et al., 2015), palmitate clearly activated PP2A in a ceramide-dependent manner. 
In this regard, palmitate-induced ceramide accumulation stimulated translocation of 
PP2A from the cytosolic compartment to the plasma membrane, where it colocalized 





eNOS from assembling with Akt and heat shock protein 90 (Hsp90), decreased the 
phosphorylation of the pool of Akt that associates directly with eNOS, and impaired full 
eNOS phosphorylation (Symons et al., 2009; Zhang et al., 2012). Importantly, and 
congruent with these findings observed in BAECs studied in vitro, the association 
between PP2A and eNOS was increased in arteries from lipid-infused and fat-fed mice in 
a ceramide-dependent manner (Bharath et al., 2015).  
 
1.1.5 Ceramide activates PP2A by disrupting the interaction  
between inhibitor 2 of PP2A (I2PP2A) and PP2A 
To this point, our results suggested strongly that FFAs in general and ceramide in 
particular cause PP2A activation and subsequent colocalization with eNOS. Next we 
focused on elucidating the mechanism whereby ceramide accumulation stimulates PP2A. 
In addition to ceramide and protein phosphatases that exist in the cytosol, various 
inhibitors of protein phosphatases are present. Mukhopadhyay et al. (2009) observed that 
inhibitor 2 of PP2A (I2PP2A) but not inhibitor 1 of PP2A (I1PP2A) is a major ceramide-
binding protein in A549 human lung cancer cells. It was reported that when ceramide 
binds to I2PP2A, the tonic restraint of I2PP2A on PP2A is removed. Multiple approaches 
were used to determine whether this mechanism operates in BAECs when ceramide 
accumulates in an endogenous manner in response to palmitate. Indeed, I2PP2A and 
PP2A are associated in the cytosol under basal, that is, control conditions. However, 
when ceramide accumulates in response to palmitate exposure, it binds preferentially 
with I2PP2A in the cytosol. When this occurs, the I2PP2A-mediated cytosolic restraint of 





associates with membrane-bound eNOS. The effects of palmitate on the cytosolic 
I2PP2A:PP2A interaction were: ameliorated in palmitate-treated BAECs by 
pharmacological and genetic procedures that limit endogenous ceramide biosynthesis; 
prevented in palmitate-treated BAECs that were transfected with catalytically-inactive 
mutant PP2A; and recapitulated in vehicle-treated ECs after siRNA-mediated suppression 
of I2PP2A gene expression. Taken together, ceramide can be elevated to an extent that 
disrupts the restraint of I2PP2A on PP2A, PP2A colocalizes with eNOS, and eNOS 
enzyme activity is compromised to an extent that NO generation is impaired (Bharath et 
al., 2015; Symons et al., 2009; Zhang et al., 2012). 
 
1.1.6 Ceramide-mediated PP2A activation is sufficient to evoke  
arterial dysfunction in obese versus lean mice  
Significant rationale exists to test whether PP2A activation contributes independently 
to arterial dysfunction in vivo. For example, Smith et al. (2006) reported suppressed 
endothelial glutathione concentrations in old versus young rats activates neutral 
sphingomyelinases that increase vascular ceramide and PP2A activity, to thereby disrupt 
the balance between p-eNOSS1177 and p-eNOST495. Although arterial dysfunction 
observed in old versus young rats was reversed in vitro by neutral sphingomyelinase 
inhibition in that study, a direct effect of PP2A on arterial function was not evaluated. 
Wu Y et al. (2007) examined the hypothesis that PP2A-mediated dephosphorylation of p-
AMPKT172 was responsible for impaired p-eNOSS1177 in vessels from mice fed a 
palmitate-rich versus oleate-rich high-fat diet. Interestingly, p-AMPKT172 and p-





retro-orbital treatment with PP2A siRNA, but the functional consequences of this 
biochemical modification of eNOS were not assessed. Mehra et al. (2014) reported that 
vascular endothelial growth factor (VEGF)-induced p-eNOSS1177 and NO generation were 
suppressed in BAECs that were coincubated with palmitate in a manner that was 
sensitive to ceramide biosynthesis (via myriocin) and PP2A (via okadaic acid) inhibition, 
confirming results reported by our laboratory using another eNOS agonist, that is, insulin 
(Symons et al., 2009).  These authors extended their in vitro findings by showing growth 
factor induced NO production was blunted in arteries from wild-type but not serine 
palmitoyltransferase long chain base subunit 2 (Sptlc2) haploinsufficient mice that 
consumed high-fat chow for 2.5 weeks, clarifying the importance of ceramide in this 
regard. In all three of these studies, however, the independent contribution from PP2A 
activation to NO-mediated arterial function was not assessed. Earlier we used 
pharmacological and genetic approaches to limit arterial ceramide accumulation, and 
therefore vascular PP2A colocalization with eNOS, to show that ceramide contributes 
importantly to endothelial dysfunction and hypertension that exist in the context of diet-
induced obesity (Zhang et al., 2012). Again, however, the contribution from PP2A 
activation per se was not evaluated in that study, and until recently, remained elusive.  
While solid rationale exists to determine whether hyperactivation of PP2A impairs 
blood vessel function, concerns regarding cytotoxicity for cantharidin-derived 
compounds, efficacy for norcantharidin-derived compounds, and target specificity for 
genetic knockout models, have precluded exploration of this important question (Bonness 
et al., 2006; Galbo et al., 2013; Götz & Schild, 2003). Investigations of PP2A activation 





Martiniova et al., 2011) and hepatic insulin resistance using rats (Galbo et al., 2013) 
reported that 3-21 day treatment with the norcantharidin analogue LB1 (Lixte 
Biotechnology Holdings, Inc., East Setauket, NY) can be administered without 
pathological evidence of toxicity. LB1 is a potent and specific inhibitor of PP2A activity 
with relatively low activity on PP1 (Lu et al., 2009; Lu et al., 2010; Martiniova et al., 
2011). We used LB1 to examine the specific contribution from PP2A to vascular 
dysfunction in the context of diet-induced obesity (Bharath et al., 2015). 
First, we demonstrated that LB1 prevented palmitate-induced PP2A activation, 
restored basal and insulin-stimulated p-eNOSS1177 and NO production, and did not 
influence upstream kinase signaling to eNOS or ceramide accumulation in BAECs. Next, 
multiple approaches established that the PP2A – mediated disruption of Akt-Hsp90-
eNOS interactions correlated with impaired p-eNOSS1177 and NO production, and this 
could be prevented by PP2A inhibition or a PP2A mutant with decreased catalytic 
activity. Third, after documenting that lard-oil infusion to intact mice increases vascular 
PP2A activity, disrupts the physical interactions among Akt-Hsp90-eNOS in the 
vasculature, and precipitates endothelium-dependent dysfunction, we showed that these 
responses could be prevented by inhibiting ceramide biosynthesis (using des1 
haploinsufficient mice) or limiting PP2A activation (i.e., LB1-treated mice). Finally, 
dysregulation of interactions among vascular Akt-Hsp90-eNOS, endothelial dysfunction, 
and systemic hypertension, all were normalized when fat-fed mice were treated with LB1 
but not vehicle (saline). Collectively, these findings indicate that PP2A activation evoked 
by palmitate in BAECs, by lard-oil infusion in mice, and by fat-feeding in mice, has 





PP2A may reverse lipotoxicity-induced vascular dysfunction (Bharath et al., 2015). 
 
1.1.7 Does long-term (i.e., 14 d) PP2A inhibition in mice  
dysregulate peripheral glucose homeostasis, impair  
insulin-mediated signal transduction in the liver,  
and lower hepatic glycogen content?  
 Results from our laboratory suggest strongly that therapeutic strategies targeted to 
lower ceramide-mediated PP2A activation might be beneficial in attenuating vascular 
complications associated with obesity, T2DM and insulin resistance (Bharath et al., 2015). 
However, while our investigation (Bharath et al., 2015) was in progress, Galbo et al. 
(2013) reported that PP2A hyperactivity is “unsuitable as a target for therapeutic 
intervention.” Evidence for this statement was provided by data indicating that impaired 
peripheral glucose tolerance, lower hepatic glycogen content, and disrupted insulin-
mediated signal transduction in the liver, exists in rats wherein PP2A was inhibited (i.e., 
LB1-treated) versus control rats (i.e., saline-treated). In this regard, three hours before 
completing a hyperinsulinemic-euglycemic clamp, male rats received 2 mg/kg LB1 or 
vehicle (saline) IP. Relative to vehicle-treated rats, LB1-treated animals displayed 8-10 
mg/dl higher fasting plasma glucose levels and required ~ 30% less infusion of [6,6-2H] 
glucose to maintain plasma glucose between 100-110 mg / dl (Figure 3A). These indices 
of whole body insulin-resistance in LB1 versus vehicle treated rats were accompanied by 
marked reductions in liver glycogen content after PP2A inhibition. For example, liver 
glycogen content in chow-fed rats was ~ 65 versus 11 ug/mg protein in response to 





~ 55 and 12 ug/mg protein in response to vehicle versus LB1 treatment, respectively. 
Therefore, LB1 markedly lowered liver glycogen to a similar extent in both chow-fed and 
fat-fed rats (Figure 3B).  
The authors attributed lower glycogen content after PP2A inhibition (Figure 3B) to 
greater insulin-stimulated phosphorylation of (i) hepatic glycogen synthase (resulting in 
inactivation and therefore decreased glycogen synthesis) and (ii) phosphorylase (resulting 
in activation and therefore increased glycogen breakdown), in LB1 versus saline-treated 
rats.  
 
1.2 Purpose of Study 
The purpose of the present study was to determine whether 14 days x 1 mg/kg LB1 
treatment in mice impairs glucose tolerance, insulin-mediated signal transduction in the 
liver, and hepatic glycogen content. Three hypotheses were tested.  
HYPOTHESIS 1: 14 days x 1 mg / kg LB1 IP impairs peripheral glucose tolerance in 
mice. To test this hypothesis, historical data sets from a glucose tolerance test and an 
insulin tolerance test obtained from mice treated ± 1 mg/kg LB1 IP for 14 days (Bharath 
et al., 2015) were reanalyzed. 
HYPOTHESIS 2: 14 days x 1 mg / kg LB1 IP treatment lowers hepatic glycogen 
content. To test this hypothesis, historical liver samples from mice treated ± 1 mg/kg LB1 
for 14 days (Bharath et al., 2015) were analyzed for glycogen content, p-Akt2S474 / Akt2, 
p-Gsk3ɑS21 / Gsk3ɑβ, and p-GSS641 / GS.  
HYPOTHESIS 3:  14 days x 1 mg / kg LB1 treatment impairs insulin-stimulated 





with LB1 or vehicle IP received insulin or vehicle-stimulation i.v. Five minutes later, 
liver segments were collected, and immunoblotting was used to assess p-Akt2S474 / Akt2, 

















Figure 1 Multiple mechanisms contribute to endothelial dysfunction that exists in 
subjects with diet-induced obesity, insulin resistance, and type 2 diabetes mellitus. Of 
these, lipotoxicity can decrease endothelial function by: (i) impairing agonist-induced 
signaling to eNOS in endothelial cells and blood vessels; (ii) increasing inflammation; (iii) 
stimulating accrual of toxic sphingolipids, for example, ceramide; (iv) promoting 
oxidative stress to an extent that overwhelms the antioxidant environment; and/or by (v) 







Figure 2 DIO elevates FFAs to an extent that increases vascular ceramide accumulation. 
Ceramide binds I2PP2A in the cytosol, and relieves the restraint of I2PP2A on PP2A. 
PP2A translocates from cytosol to membrane, binds eNOS, and disrupt the Akt-Hsp90-
eNOS interaction to an extent that impairs NO generation, leading to endothelial 




Figure 3 Rats consumed chow (Con) or high fat (HF) diet for 3 days. Three hours prior to 
a hyperinsulinemic-euglycemic clamp rats were treated with vehicle (Veh) or LB1. (A) A 
lower glucose infusion rate was required to maintain euglycemia in LB1 versus Veh- 
treated rats, regardless of diet. (B) Segments of liver were obtained immediately 
following the hyperinsulinemic-euglycemic clamp. Liver glycogen content was lower in 
LB1 versus Veh-treated rats, regardless of diet. Results are mean ± SEM. *P <0.05 LB1 












MATERIALS AND METHODS 
 
2.1 Cohort 1 
2.1.1 Animals 
All protocols were approved by the University of Utah (UU) Institutional Animal 
Care and Use Committee (IACUC; 13-06004). Mice were maintained in a temperature-
controlled barrier facility with a 12-hr light/dark cycle and were given free access to food 
and water. Seven-week old male C57BL/6J mice (n =24) were obtained from the Jackson 
Laboratory (Bar Harbor, ME) and consumed standard rodent chow (D12450B, Research 
Diets, Inc., New Brunswick, NJ) containing (kcal) 10% fat, 70% carbohydrate, and 20% 
protein (control diet; CON) during a one-week quarantine period. Next, mice either 
continued the CON diet or were placed on high fat chow (D12451, Research Diets, Inc., 
New Brunswick, NJ) containing (kcal) 45% fat, 35% carbohydrate, and 20% protein for 
12 weeks [high fat (HF) diet] (Bharath et al., 2015; Symons et al., 2009; Zhang et al., 
2012). For the final 14 days, subgroups of CON and HF mice received vehicle (saline) or 
LB1 (1 mg/kg/day) (Bharath et al., 2015; Lu et al., 2009; Lu et al., 2010; Martiniova et al., 
2011). Next, mice completed a glucose tolerance test (GTT) and insulin tolerance test 
(ITT; described below). At least 48 hr following the GTT or ITT, mice were anesthetized 





excised and placed in eppendorf tubes, frozen in liquid nitrogen, and stored at -80ºC. 
Segments of liver were used for immunoblotting and to quantify glycogen content.  
 
2.1.2 Glucose Tolerance Test (GTT)   
Mice were made to fast for 6 hr by removal to a clean cage without food at the end of 
their dark (feeding) cycle, that is, 6:00 AM. After 6 hr, mice were weighed, and blood 
glucose was determined using a glucometer (Onetouch Ultra2; Life Scan, Inc., Milpitas, 
CA) via a tail clip (i.e., 0-min). Next, glucose (1 mg/g, IP) was administered to conscious 
animals and blood glucose determined after 5, 15, 30, 60, and 120-min. At 0-min, an 
extra volume of blood (∼50ul) was obtained. Samples were centrifuged for 10 min x 
3000 rpm at 4°C to assess serum insulin (ELISA, Linco, Billerica, MA) and free fatty 
acids (FFAs; colorimetric, half-micro test, Roche Diagnostics, Indianapolis, IN) (Bharath 
et al., 2015; Symons et al., 2009; Zhang et al., 2012). Results were used to calculate the 
homeostasis model assessment of insulin resistance (HOMA-IR), that is, fasting glucose 
(mmol/L) × fasting serum insulin (mU/L) divided by 22.5 (Matthews, et al., 1985). Blood 
glucose at each time point during the GTT, and the calculated HOMA-IR, was compared 
between Con-Veh and Con-LB1 mice, and HF-Veh and HF-LB1 mice.  
 
2.1.3 Insulin Tolerance Test (ITT) 
Mice were made to fast for 4 hr by removal to a clean cage at the end of their dark 
(feeding) cycle. After 4 hr, mice were weighed, a blood sample was obtained via tail clip 
(i.e., 0-min), and glucose was measured using a glucometer (Onetouch Ultra2; Life Scan, 





(0.75 U/kg body weight; IP), and blood glucose was assessed via tail clip 5, 15, 20, 25, 
and 30- min later (Bharath et al., 2015; Symons et al., 2009; Zhang et al., 2012). Blood 
glucose at each time point was compared between Con-Veh and Con-LB1 mice, and HF-
Veh and HF-LB1 mice. 
 
2.1.4 Glycogen content 
Segments of liver were obtained from Con-Veh, Con-LB1, HF-Veh, and HF-LB1 
mice (Bharath et al., 2015). Liver glycogen content was measured using a commercially 
available kit (Cayman Chemical, Ann Arbor, Michigan) according to the manufacturer’s 
instructions (Kim, Kim, & Park, 2012). In brief, 300 mg of minced liver tissue was 
combined with 2 ml of Halt protease and phosphatase inhibitor cocktail (Thermo 
Scientific, Rockford, IL). After homogenization and sonication on ice, samples were 
centrifuged for 10 min x 3000 rpm at 4°C. Aliquots of supernatant were diluted 1:10 – 
1:100, depending on the protein concentration obtained, and glycogen was assessed.  
 
2.1.5 Immunoblotting 
Segments of liver were obtained from Con-Veh, Con-LB1, HF-Veh, and HF-LB1 
mice that were used to assess GTT and ITT. (Bharath et al., 2015) Liver tissue was 
homogenized in ice-cold homogenization cell lysis buffer pH 7.2-7.4 (0.01 M Hepes, 
0.05 M sodium fluoride, 0.002 M EDTA, 0.05M Disodium pyrophosphate, 0.15M 
sodium chloride, 0.02M Tris-HCl ,1% Triton X-100), with Halt protease and phosphatase 
inhibitor cocktail (Thermo Scientific, Rockford, IL). Tissues were sonicated on ice and 





supernatant were stored at −80°C for later immunoblotting and protein analyses (Bharath 
et al., 2015; Symons et al., 2009; Zhang et al., 2012).  
Protein concentration for immunoblotting was determined using a Pierce™ BCA 
Protein Assay Kit (Thermo Scientific, Rockford, IL). Western Blotting was used to detect 
specific proteins in each tissue sample. Proteins were separated by the length of the 
polypeptide using gel electrophoresis. Protein phosphorylation was determined using 
western blot procedures. Equal amounts of protein were suspended in loading buffer 
containing Tris-Glycine SDS (Novex, Life Tech, Carlsbad, CA), incubated for 5 min in a 
37°C water bath, and 14.4 mM 2-mercaptoethanol was added. Resolved proteins in 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) were transferred 
to a polyvinylidene difluoride (PVDF) membrane (Millipore Immobilon-P Transfer 
membrane; Millipore Corp., Billerica, MA) for overnight incubation at 4°C. Following 
the transfer, membranes were blocked with 5% bovine serum albumin (BSA) in Tris-
buffered saline with 1% Tween-20 (TBST) for 45 min at room temperature. Blocked 
membranes then incubated with the respective primary antibody for phosphorylated 
proteins overnight at 4°C. Next, membranes were washed with TBST (3× 15 min), and 
incubated with the appropriate secondary antibody conjugated to horseradish peroxidase-
conjugated antirabbit IgG (Rockland, Limerick, PA) or antimouse IgG (Rockland, 
Limerick, PA) for 1 hour at room temperature. Membranes were washed with TBST (4 × 
5 min) and scanned (Licor Odyssey scanner) (Bharath et al., 2015; Symons et al., 2009; 
Zhang et al., 2012; Zhang et al., 2009). Dilution conditions were: 1: 1000, 5% 
BSA/TBST, 10% gel for p-Akt2S474, AKT2, p-GSK3αS21, p-GSS641, GS, GAPDH (Cell 





Cruz, CA) (Bharath et al., 2015; Symons et al., 2009; Zhang et al., 2012; Zhang et al., 
2009).   
 
2.2 Cohort 2 
2.2.1 Animals 
All protocols were approved by UU IACUC protocol # 13-06004. 17-week-old male 
C57BL/6J mice (n =20) were familiarized for 1 week, injected with vehicle (saline; n =10) 
or LB1 (1 mg/kg/day; n =10; IP) for 14 consecutive days (Bharath et al., 2015), and 
weighed daily. Next, (i) body composition was assessed using nuclear magnetic 
resonance imaging (NMR) (Bharath et al., 2015) and compared between vehicle-treated 
(n =10) and LB1-treated (n =10) mice, (ii) random-fed and 14 hr fasted blood glucose 
measurements were collected via tail clip procedures (Bharath et al., 2015; Symons et al., 
2009; Zhang et al., 2012) and compared between vehicle-treated (n =10) and LB1-treated 
(n =10) mice, and (iii) liver samples were obtained from anesthetized, vehicle-treated 
mice following i.v., saline (n =5) or insulin (n =5) administration, and LB1-treated mice 
following i.v., saline (n =5) or insulin (n =5) administration. Details are provided below. 
 
2.2.2 Body composition  
Lean mass, fat mass, and fluid mass were assessed in conscious mice via NMR 
(Bruker Minispec Model Mq series 7.5; Bruker Optics, Inc., Billerica, MA) after 14 







2.2.3 Insulin-mediated signal transduction 
Mice were treated for 14 consecutive days with vehicle or LB1. On day 15, after a 6- 
hr fast, mice were anesthetized using 2-5% isoflurane. When an appropriate plane of 
anesthesia was achieved, the chest was opened and insulin (Humulin 3.3mU / g body 
weight) or vehicle (saline) was administered i.v (Zhu et al., 2013). Five minutes later, the 
heart was excised and segments of liver were collected to assess p-Akt2S474 / Akt2, p-
GSK3ɑS21 / GSK3ɑ, and p-GSS641 / GS, (Cell Signaling Technology, Danvers, MA). Each 
endpoint was assessed in four groups, that is, vehicle-treated mice ± insulin and LB1-
treated mice ± insulin (n =5 each) (Symons et al., 2009; Zhu et al., 2013).   
 
2.2.4 Immunoblotting 
Segments of liver were prepared and processed for immunoblotting as we described 
earlier (Bharath et al., 2015; Symons et al., 2009; Zhang et al., 2012; Zhang et al., 2009) 
 
2.3 Statistical Analyses 
Data are presented as mean ± standard error of the mean (SEM). Comparison of one 
endpoint (e.g., lean mass) between groups (e.g., vehicle-treated vs. LB1 treated mice) 
was made using an unpaired t test. Comparison of multiple time-points (e.g., blood 
glucose at 0, 5, 15, 30, 60, and 120-min) between two groups (e.g., vehicle-treated and 
LB1 treated mice) was assessed using a two-way repeated measures analysis of variance. 
Comparison of one endpoint (e.g., liver p-GSS641) among four groups (e.g., Veh-saline, 
Veh-insulin, LB1-saline, LB1-insulin) was made using a one-way analysis of variance. 





significant main effects were obtained. Statistics were performed using GraphPad Prism 
version 7.  
To determine the fold change from Con-Veh mice regarding the measured endpoints 
(i.e., hepatic glycogen content, p-Akt2S474 / Akt2, p-Gsk3α S21 / Gsk3αβ, and p-GSS641 / 
GS) observed in Con-LB1, HF-Veh, and HF-LB1 animals (Hypotheses 1 and 2), the 
following approach was used.  p-Akt2S474 / total Akt2 is used as an example. The 
densitometric ratios for p-Akt2S474 / Akt2 were determined for all mice within the Con-
Veh group. The group mean average was calculated and normalized to 1.0, by dividing 
each ratio by the group mean value. Next, the ratio of p-Akt2S474 / Akt2 was determined 
for samples representing the other groups (i.e., Con-LB1, HF-Veh, and HF-LB1). Each of 
these values was divided by the group mean p-Akt2S474 / Akt2 obtained from the Con-
Veh group, and expressed as fold-change relative to Con-Veh (Bharath et al., 2015; 
Symons et al., 2009; Zhang et al., 2012; Zhang et al., 2009).  
To determine the fold change from SAL-Veh mice regarding the measured endpoints 
(i.e., p-Akt2S474 / Akt2, p-Gsk3α S21 / Gsk3αβ, and p-GSS641 / GS) observed in SAL-ins, 
LB1-Veh, and LB1-ins animals (Hypothesis 3), the following approach was used.  p-
Akt2S474 / total Akt2 is used as an example. The densitometric ratios for p-Akt2S474 / Akt2 
were determined for all mice within the SAL-Veh group. The group mean average was 
calculated and normalized to 1.0, by dividing each ratio by the group mean value. Next, 
the ratio of p-Akt2S474 / Akt2 was determined for samples representing the other groups 
(i.e., SAL-ins, LB1-Veh, and LB1-ins). Each of these values was divided by the group 





relative to SAL-Veh group (Bharath et al., 2015; Symons et al., 2009; Zhang et al., 2012; 














3.1 Peripheral Glucose Homeostasis 
3.1.1 Glucose Tolerance Test (GTT)  
The purpose of this experiment was to test the hypothesis that 14 days of LB1 
treatment impairs peripheral glucose tolerance in lean and obese mice. No differences in 
blood glucose between CON-Veh and CON-LB1 mice were obtained at any time point 
during the GTT (Figure 4A).  Blood glucose was lower (p <0.05) in HF-LB1 versus HF-
Veh mice at 60 and 120 min of the GTT (Figure 4B).  
Fasting blood glucose (mg / dl), that is, the “0” time point, was similar in CON-Veh 
(117 ± 11) versus CON-LB1 (111 ± 13) mice, and in HF-Veh (133 ± 4) versus HF-LB1 
(127 ± 18) mice. Fasting serum insulin (ng/ml) that is, the “0” time point, was similar in 
CON-Veh (0.59 ± 0.06) versus CON-LB1 (0.46 ± 0.04) mice, and was lower (p <0.05) in 
HF-LB1 (0.35 ± 0.01) versus HF-Veh (0.68 ± 0.04) mice. HOMA-IR, calculated using 
fasting glucose and insulin, was similar between CON-Veh (4.42 ± 0.70) and CON-LB1 
(3.19 ± 0.59) mice, but was lower (p <0.05) in HF-LB1 (2.75 ± 0.42) versus HF-Veh 







3.1.2 Insulin Tolerance Test ( ITT) 
The purpose of this experiment was to test the hypothesis that 14 days of LB1 
treatment impairs peripheral sensitivity to insulin in lean and obese mice. Fasting blood 
glucose (mg / dl), that is, the “0” time point, was lower (p <0.05) in CON-LB1 (76 ± 4) 
versus CON-Veh (99 ± 6) mice, and in HF-LB1 (70 ± 5) versus HF-Veh (110 ± 6) mice. 
Blood glucose was lower (p <0.05) at 5, 10, 15 and 20-min following insulin 
administration in CON-LB1 versus CON-Veh mice (Figure 5A). Likewise, blood glucose 
was lower (p <0.05) in HF-LB1 versus HF-Veh mice 5,10, 20, and 25-min following 
insulin administration (Figure 5B).  
To control for differences in fasting blood glucose that existed between lean and 
obese mice treated with Veh (Figure 5A) and LB1 (Figure 5B), the “0” time point blood 
glucose for all mice was converted to 100%, and insulin-mediated changes in circulating 
blood glucose in the respective groups was expressed relative to 100%. Blood glucose 
was lower (p <0.05) at 5 and 20 min following insulin administration in CON-LB1 versus 
CON-Veh mice (Figure 5C). Likewise, blood glucose was lower (p <0.05) in HF-LB1 
versus HF-Veh mice 20 min following insulin administration (Figure 5D). Together, 
these data do not support the original hypothesis.  
 
3.2 Hepatic Glycogen Content 
3.2.1 Glycogen content in liver 
The purpose of this experiment was to test the hypothesis that 14 days of LB1 
treatment lowers liver glycogen content in mice.  No differences existed among groups 





hypothesis.      
 
 
3.2.2  Basal p-Akt2 S474, p-Gsk3α S21, and p-GS S641 in liver  
The purpose of this experiment was to test the hypothesis that 14 days of LB1 
treatment increases hepatic p-Akt2S474 / Akt2, p-Gsk3α S21 / Gsk3αβ, and p-GSS641 / GS in 
mice. No changes were observed among groups concerning these endpoints (Figures 7A-
7C).  Together, these results do not support the original hypothesis.  
  
3.3 Insulin-Mediated Signal Transduction in Liver 
3.3.1 Basal and insulin-stimulated p-Akt2 S474, p-Gsk3α S21,  
and p-GS S641 in liver 
The purpose of this experiment was to test the hypothesis that 14 days of LB1 
treatment impairs insulin-stimulated p-Akt2S474 / Akt2, p-Gsk3αS21 / Gsk3α, and p-GSS641 
/ GS in the liver. Fourteen days of LB1 treatment did not alter body mass (Figure 8A), 
body composition (Figure 8B,C), or random-fed blood glucose (Figure 8D). On Day 15, 
fasting blood glucose was lower (p <0.05) in LB1 versus Veh-treated mice (Figure 8D). 
To assess insulin-mediated signal transduction in the liver, vehicle-treated mice received 
i.v. saline (n =5) or insulin (n =5), and LB1-treated mice received i.v. saline (n =5) or 
insulin (n =5). Compared to vehicle-treated mice given saline, insulin increased (p <0.05) 
p-Akt2S474 / Akt2, but neither p-Gsk3αS21 / Gsk3α nor p-GSS641 / GS were altered. 
Compared to LB1-treated mice given saline, insulin increased (p <0.05) p-Akt2S474 / Akt2, 
but neither p-Gsk3αS21 / Gsk3α nor p-GSS641 / GS were altered (Figure 9A-9C). The 





between Veh-treated 5.6±1.22-fold and LB1-treated 3.4±0.37-fold mice. Taken together, 
results concerning insulin-mediated p-Akt2S474 / Akt2, p-Gsk3αS21 / Gsk3α, and p-GSS641 


























Figure 4 Blood glucose during the glucose tolerance test (GTT). Blood glucose was 
similar in lean mice regardless of LB1 treatment (A). Blood glucose was lower (p <0.05) 
in obese mice treated with saline versus LB1 at 60 and 120 min (B). HOMA-IR was 
similar in lean mice regardless of LB1 treatment, whereas HOMA-IR was lower (p <0.05) 
in obese mice treated with LB1 versus. Veh. (C). CON, mice that consumed standard 
chow; HF, mice that consumed high fat chow, n =6-8 mice per group. Veh, vehicle i.e., 
saline; LB1, PP2A inhibitor. Results represent mean ± SEM. *P  < 0.05 versus Con-Veh; 











Figure 5 Blood glucose during the insulin tolerance test (ITT). Blood glucose was lower 
(p <0.05) before (i.e., 0-min) and 5, 10, 15 and 20-min postinsulin administration in 
CON-LB1 versus CON-Veh mice (A). Blood glucose was lower (p <0.05) before (i.e., 0-
min) and 5, 10, 20, and 25-min postinsulin administration in HF-LB1 versus HF-Veh 
mice (B). Blood glucose was lower (p <0.05) at 5 and 20 min postinsulin administration 
in CON-LB1 versus CON-Veh mice (C). Blood glucose was lower (p <0.05) at 20-min 
postinsulin administration in HF-LB1 versus HF-Veh mice (D).  CON, mice that 
consumed standard chow; HF, mice that consumed high fat chow, n =5-7 mice per group. 
Veh, vehicle, that is, saline; LB1, PP2A inhibitor. Results represent mean ± SEM. *P  < 









Figure 6 Liver glycogen content. No differences among groups were observed regarding 
liver glycogen content. CON, mice that consumed standard chow; HF, mice that 
consumed high fat chow. Veh, vehicle, that is, saline; LB1, PP2A inhibitor. Results 
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Figure 7 Kinase regulation of hepatic glycogen content. Basal p-Akt2S474 / Akt2, p-
Gsk3αβS21 / Gsk3α, and p-GSS641 / GS were similar in lean and obese mice regardless of 









Figure 8 Body mass, body composition, and blood glucose. PP2A inhibition via LB1 
treatment for 14 days does not alter body mass (A), body composition (B, C), or random-
fed blood glucose (D). However, fasted blood glucose was lower in LB1 versus Veh-
treated mice. Veh; vehicle (saline) treatment. Results represent mean ± SEM. n =10 mice 










Figure  9  Insulin-mediated signal transduction. Ins (insulin) increased (p <0.05) hepatic 
p-Akt2S474 / Akt2 regardless of LB1 treatment. Neither p-Gsk3αS21 / Gsk3α nor p-GSS641/ 
GS were increased by insulin. Results represent mean ± SEM, n =4-5 mice per group. *P  































4.1 Summary of Main Findings 
Identifying new targets for therapeutic intervention that might attenuate 
cardiovascular complications associated with type 2 diabetes is needed. In an earlier 
report we showed that mice treated with a potent and selective small molecule inhibitor 
(LB1; Lixte Biotechnology Holdings, Inc., East Setauket, NY; 1 mg/kg IP) of protein 
phosphatase 2A (PP2A) for the last 14 days of an obesogenic diet (12 weeks of fat-
feeding) did not display vascular PP2A hyperactivation, endothelial dysfunction, or 
hypertension that otherwise developed in fat-fed mice treated with vehicle (Bharath et al., 
2015). These results provide strong proof of concept that PP2A inhibition should be 
considered further as a target for intervention in the context of lipotoxicity-induced 
cardiovascular complications. Conversely, findings from another laboratory indicated that 
LB1 evokes hyperglycemia, glucose intolerance, and hepatic glycogen depletion in rats, 
and the authors concluded that targeting PP2A hyperactivation should not be considered 
as a therapeutic intervention (Galbo et al., 2013). Important differences between the two 
investigations exist, for example, species studied, fat-feeding protocol, LB1 dose, and/or 
LB1 duration of treatment. The purpose of this study was to determine whether LB1 





content; and (iii) insulin-mediated signal transduction in the liver of mice. Our results 
indicate that 1 mg/kg LB1 IP x 14 days attenuates vascular PP2A activity, but does not 
adversely affect circulating blood glucose, the ability of mice to clear a glucose load, or 
insulin-mediated signal transduction in the liver. As such, we believe that further research 
into the effectiveness and practicality of PP2A inhibition in cardiovascular pathologies 
related to PP2A hyperactivation is warranted.  
 
4.2 Peripheral Glucose Homeostasis 
Insulin stimulates glycogen synthesis by phosphorylation (activation) of Akt, which 
phosphorylates (inactivates) Gsk3α. Since Gsk3α phosphorylates (inactivates) glycogen 
synthase (GS), the result of insulin-mediated Akt phosphorylation is increased GS 
activity and glycogen synthesis. This process is impaired in the context of insulin 
resistance associated with type 2 diabetes mellitus, at least, in part, at the level of Akt 
phosphorylation. While Akt can be stimulated by insulin-receptor mediated activation, it 
is concurrently under negative control by phosphatases, particularly PP2A. Because 
lipotoxicity increases PP2A activity, it is reasonable to hypothesize that heightened PP2A 
activity might contribute to decreased Akt phosphorylation in the context of insulin 
resistance. Galbo et al. (2013) sought to determine whether PP2A inhibition has 
therapeutic applications in this regard. Indeed, the authors demonstrated that 3 hr x 2 
mg/kg LB1, a PP2A inhibitor, increased liver p-Akt2 by ~ 35% in a well-accepted model 
of hepatic insulin resistance, that is, rats fed high-fat chow for 3 days. Using this model, 
the authors investigated whether improved hepatic insulin signaling might enhance 





euglycemic clamp, rats received 2 mg/kg LB1 or vehicle (saline) IP. Contrary to their 
hypothesis, LB1-treated animals displayed 8-10 mg/dl higher fasting plasma glucose 
levels, and required ~ 30% less infusion of [6,6-2H] glucose to maintain plasma glucose 
between 100-110 mg / dl, versus vehicle-treated rats. To determine if relatively long term 
LB1 treatment with a lower yet efficacious dose of LB1 recapitulates these deleterious 
findings in mice, we performed glucose and insulin tolerance testing in lean and obese 
mice treated for the last 14 days of a 12-week protocol with 1 mg/kg LB1 or vehicle. 
Contrary to our hypothesis, which was based on results from Galbo et al. (2013), results 
from a glucose tolerance test and insulin tolerance indicated that LB1 treatment does not 
adversely affect the ability of lean or obese mice to process a glucose or insulin load, 
when compared to findings from lean and obese mice treated with saline. In fact, under 
fasting conditions, and at several time points during the GTT and ITT, blood glucose was 
lower in LB1 versus saline-treated mice.  
 
4.3 Hepatic Glycogen Content and Insulin-Mediated Signal  
Transduction in the Liver 
Insulin stimulates phosphorylation (activation) of Akt which leads to phosphorylation 
(inactivation) of Gsk3α. Because Gsk3α normally phosphorylates (inhibits) glycogen 
synthase, the end result of insulin stimulation is glycogen synthesis. Galbo et al. (2013) 
showed that LB1 treatment markedly lowers liver glycogen content in lean and obese rats, 
despite the fact that PP2A inhibition increased insulin-stimulated p-Akt2 and p-Gsk3α. A 
further exploration of mechanisms in that study revealed that PP2A inhibition 





(resulting in inactivation and therefore decreased glycogen synthesis) and (ii) 
phosphorylase (resulting in activation and therefore increased glycogen breakdown). To 
investigate this in the context of our experimental conditions, liver glycogen content was 
quantified in lean and obese mice treated with LB1 or vehicle for 14 consecutive days. 
No differences were observed among groups. Because we originally hypothesized that 
liver glycogen content would be lower in LB1 versus vehicle-treated mice regardless of 
diet, we examined several nodes in the insulin-mediated signaling pathway under basal 
conditions that previously had been implicated by Galbo et al (2013). Congruent with our 
findings concerning hepatic glycogen content and peripheral glucose homeostasis, yet 
contrary to results presented by Galbo et al. (2013), we observed that basal p-Akt2S474 /  
Akt2, p-Gsk3α S21 / Gsk3αβ, and p-GSS641 / GS were similar in liver obtained from lean 
and obese mice regardless of LB1 treatment. While these results suggest that insulin-
mediated signal transduction is not altered by LB1 treatment in the context of our 
experimental conditions under basal conditions, it is not unreasonable to hypothesize that 
the situation could be different in response to acute insulin stimulation. We investigated 
this possibility in a separate cohort of mice. Specifically, vehicle-treated mice received 
acute administration of saline or insulin i.v., and LB1-treated mice received acute 
administration of saline or insulin i.v. Compared to mice given saline, insulin increased 
p-Akt2S474 / Akt2 to the same extent in lean and obese mice regardless of LB1 treatment, 
whereas neither p-Gsk3αS21 / Gsk3α nor p-GSS641 / GS were altered. Collectively, a 14 
day regimen of 1 mg/kg LB1 does not alter hepatic glycogen content under basal 
conditions, or p-Akt2S474 / Akt2, p-Gsk3αS21 / Gsk3α, or p-GSS641 / GS under basal or 





Several reasonable explanations exist for why 2 mg/kg LB1 x 3 hr might have 
deleterious consequences concerning peripheral glucose homeostasis, hepatic glycogen 
content, and insulin-mediated signal transduction in rats, whereas 1 mg/kg LB1 x 14 days 
might not evoke adverse consequences. These explanations include the: (i) species 
studied (rats vs. mice); (ii) dose / duration of LB1 treatment (2 mg/kg x 3 hr vs. 1 mg/kg 
x 14 days); (iii) methods to assess peripheral glucose homeostasis (hyperinsulinemic-
euglycemic clamp vs. glucose tolerance test and insulin tolerance test); (iv) procedures to 
evaluate insulin-mediated signal transduction (4 mU/kg/min insulin x 20 min in 
conscious rats vs. 3.3mU / g body weight i.v. in anesthetized mice). 
 
4.4 Conclusion 
In conclusion, we report that PP2A inhibition is not associated with impaired 
peripheral glucose, hepatic glycogen content, and insulin-mediated signal transduction in 
the liver. Therefore, our results suggest that PP2A hyperactivation should be considered 
further as a therapeutic target for intervention, and that lowering PP2A activation might 
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